Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Henry

Showing results (31-40 of 155) with videos related to

Pageof 16
Sort By:
Clinical Therapeutics|April 13, 2013
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetesRobert R Henry, Douglas Logan, Thomas Alessi, et al.
Diabetes Technology & Therapeutics|August 16, 2016
Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 StudyRobert R Henry, Eric J Klein, Jenny Han, et al.
The Journal of Clinical Endocrinology and Metabolism|April 28, 2012
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trialRobert R Henry, Sunder Mudaliar, Linda Kanitra, et al.
Diabetes Care|October 22, 2015
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 DiabetesRobert R Henry, Payal Thakkar, Cindy Tong, et al.
Metabolism: Clinical and Experimental|August 21, 2013
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatmentTheodore P Ciaraldi, Vanita Aroda, Sunder R Mudaliar, et al.
Plos One|July 26, 2016
Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 DiabetesTheodore P Ciaraldi, Alexander J Ryan, Sunder R Mudaliar, et al.
Diabetes Care|March 19, 2016
Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 DiabetesAnne L Peters, Robert R Henry, Payal Thakkar, et al.
Diabetes, Obesity & Metabolism|January 19, 2017
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot studyRobert R Henry, Paresh Dandona, Jeremy Pettus, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2008
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistanceTheodore P Ciaraldi, Vanita Aroda, Sunder Mudaliar, et al.
Endocrinology|June 16, 2007
Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cellsTheodore P Ciaraldi, Svetlana E Nikoulina, Rahil A Bandukwala, et al.
Pageof 16

Showing results (31-40 of 155) with videos related to

Sort By:
Pageof 16
Clinical Therapeutics|April 13, 2013
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetesRobert R Henry, Douglas Logan, Thomas Alessi, et al.
Diabetes Technology & Therapeutics|August 16, 2016
Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 StudyRobert R Henry, Eric J Klein, Jenny Han, et al.
The Journal of Clinical Endocrinology and Metabolism|April 28, 2012
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trialRobert R Henry, Sunder Mudaliar, Linda Kanitra, et al.
Diabetes Care|October 22, 2015
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 DiabetesRobert R Henry, Payal Thakkar, Cindy Tong, et al.
Metabolism: Clinical and Experimental|August 21, 2013
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatmentTheodore P Ciaraldi, Vanita Aroda, Sunder R Mudaliar, et al.
Plos One|July 26, 2016
Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 DiabetesTheodore P Ciaraldi, Alexander J Ryan, Sunder R Mudaliar, et al.
Diabetes Care|March 19, 2016
Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 DiabetesAnne L Peters, Robert R Henry, Payal Thakkar, et al.
Diabetes, Obesity & Metabolism|January 19, 2017
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot studyRobert R Henry, Paresh Dandona, Jeremy Pettus, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2008
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistanceTheodore P Ciaraldi, Vanita Aroda, Sunder Mudaliar, et al.
Endocrinology|June 16, 2007
Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cellsTheodore P Ciaraldi, Svetlana E Nikoulina, Rahil A Bandukwala, et al.
Pageof 16